Sym004

Sym004 is a 1:1 mixture of two recombinant, human-mouse chimeric mAbs directed against nonoverlapping EGFR epitopes (mAb992 and mAb1024) . Sym004 is ability to mediate rapid EGFR internalization and subsequent degradation of internalized receptors via EGFR cross-linking. Sym004 can be used for the study of metastatic colorectal cancer, head and neck (H&N) and lung cancer[1][2].

Product Specifications

UNSPSC

12352203

Target

EGFR

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

References & Citations

[1]Dienstmann R, et al. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discov. 2015 Jun;5 (6) :598-609.|[2]Free Jarob Saker, et al. Abstract 1027: EGFR targeting antibody SYM004 causes radiosensitization in tumor cells expressing wild-type K-Ras via modulation of MAPK signaling. Cancer Res (2013) 73 (8_Supplement) : 1027.